LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN

N/A

Manufactured by Novartis Pharmaceuticals Corporation

14,999 FDA adverse event reports analyzed

Last updated: 2026-04-14

About LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novartis Pharmaceuticals Corporation. The most commonly reported adverse reactions for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN include GENERAL PHYSICAL HEALTH DETERIORATION, ILL-DEFINED DISORDER, DEATH, DISEASE PROGRESSION, MALIGNANT NEOPLASM PROGRESSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN.

Top Adverse Reactions

GENERAL PHYSICAL HEALTH DETERIORATION5,025 reports
ILL DEFINED DISORDER3,611 reports
DEATH1,209 reports
DISEASE PROGRESSION296 reports
MALIGNANT NEOPLASM PROGRESSION266 reports
LABORATORY TEST ABNORMAL245 reports
PROSTATIC SPECIFIC ANTIGEN INCREASED229 reports
FATIGUE203 reports
ANAEMIA165 reports
COVID 19140 reports
ILLNESS137 reports
PLATELET COUNT DECREASED137 reports
THROMBOCYTOPENIA123 reports
NAUSEA122 reports
HORMONE REFRACTORY PROSTATE CANCER117 reports
HAEMOGLOBIN DECREASED116 reports
DRUG INEFFECTIVE114 reports
PROSTATE CANCER112 reports
ASTHENIA101 reports
MALAISE100 reports
DRY MOUTH96 reports
SARS COV 2 TEST POSITIVE85 reports
PAIN81 reports
METASTASES TO BONE71 reports
PROSTATE CANCER METASTATIC69 reports
VOMITING69 reports
PANCYTOPENIA64 reports
DECREASED APPETITE63 reports
FULL BLOOD COUNT DECREASED54 reports
WEIGHT DECREASED54 reports
OFF LABEL USE50 reports
PNEUMONIA50 reports
BACK PAIN49 reports
DIARRHOEA49 reports
FALL48 reports
DYSPNOEA45 reports
DRUG INTOLERANCE41 reports
METASTASES TO LIVER41 reports
PYREXIA37 reports
WHITE BLOOD CELL COUNT DECREASED37 reports
ACUTE KIDNEY INJURY36 reports
CONSTIPATION36 reports
RENAL FAILURE36 reports
RENAL IMPAIRMENT35 reports
MYELOSUPPRESSION34 reports
ARTHRALGIA31 reports
CONDITION AGGRAVATED31 reports
THERAPY NON RESPONDER31 reports
LEUKOPENIA29 reports
BONE PAIN28 reports
DEHYDRATION28 reports
INFECTION28 reports
BLOOD TEST ABNORMAL27 reports
HAEMATURIA27 reports
NEUROPATHY PERIPHERAL26 reports
SEPSIS26 reports
URINARY TRACT INFECTION26 reports
LOSS OF LIBIDO25 reports
TOXICITY TO VARIOUS AGENTS25 reports
CYTOPENIA24 reports
NEUTROPENIA23 reports
PAIN IN EXTREMITY23 reports
HEADACHE22 reports
PROSTATIC SPECIFIC ANTIGEN ABNORMAL22 reports
NEOPLASM MALIGNANT21 reports
ABDOMINAL PAIN20 reports
CEREBROVASCULAR ACCIDENT20 reports
DIZZINESS20 reports
HAEMATOTOXICITY20 reports
HYPOTENSION20 reports
PLEURAL EFFUSION20 reports
BLOOD ALKALINE PHOSPHATASE INCREASED19 reports
FULL BLOOD COUNT ABNORMAL19 reports
MYOCARDIAL INFARCTION19 reports
BLOOD CREATININE INCREASED18 reports
HAEMORRHAGE18 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION18 reports
ATRIAL FIBRILLATION17 reports
METASTASES TO SPINE17 reports
RASH17 reports
HOT FLUSH16 reports
PROSTATIC SPECIFIC ANTIGEN DECREASED16 reports
RED BLOOD CELL COUNT DECREASED16 reports
SUBDURAL HAEMATOMA16 reports
URINARY RETENTION16 reports
ASPARTATE AMINOTRANSFERASE INCREASED15 reports
CARDIAC FAILURE15 reports
HAEMATOCRIT DECREASED15 reports
INFLUENZA15 reports
NEUTROPHIL COUNT DECREASED15 reports
PERIPHERAL SWELLING15 reports
ACQUIRED HAEMOPHILIA14 reports
CHEST PAIN14 reports
CONFUSIONAL STATE14 reports
FEELING ABNORMAL14 reports
GAIT DISTURBANCE14 reports
HIP FRACTURE14 reports
INSOMNIA14 reports
METASTASES TO LYMPH NODES14 reports
PEPTIC ULCER14 reports

Report Outcomes

Out of 11,564 classified reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:

Serious 24.3%Non-Serious 75.7%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male1,993 (99.0%)
Female20 (1.0%)

Reports by Age

Age 7249 reports
Age 7444 reports
Age 7744 reports
Age 7641 reports
Age 7040 reports
Age 6536 reports
Age 6834 reports
Age 7534 reports
Age 6633 reports
Age 7833 reports
Age 6732 reports
Age 7332 reports
Age 7928 reports
Age 8128 reports
Age 8027 reports
Age 6026 reports
Age 8226 reports
Age 7125 reports
Age 8721 reports
Age 6920 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN?

This profile reflects 14,999 FDA FAERS reports that mention LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN?

Frequently reported terms in FAERS include GENERAL PHYSICAL HEALTH DETERIORATION, ILL-DEFINED DISORDER, DEATH, DISEASE PROGRESSION, MALIGNANT NEOPLASM PROGRESSION, LABORATORY TEST ABNORMAL. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN?

Labeling and FAERS entries often list Novartis Pharmaceuticals Corporation in connection with LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.